Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Tysabri safety evaluation complete; no new confirmed cases of PML
November 18th, 2005
Elan Corp., plc, (ELN) and Biogen Idec (BIIB) announced that findings from their safety evaluation of Tysabri (natalizumab) in patients with Crohn disease (CD) and rheumatoid arthritis (RA) resulted in no new confirmed cases of progressive multifocal leukoencephalopathy (PML). The companies have previously reported that findings from their safety evaluation of Tysabri in patients with multiple sclerosis (MS) resulted in no new confirmed cases of PML. Three confirmed cases of PML were previously reported, two of which were fatal. The Tysabri safety evaluation is now complete. On September 26, 2005 the companies announced that they submitted a...
Source: Drug Week (2005-11-18)
|
